Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atrocoxib-P is an oral fixed-dose combination tablet developed and marketed by Atro Pharma, a pharmaceutical company based in New Delhi, India. It contains etoricoxib, a highly selective cyclooxygenase-2 (COX-2) inhibitor, and paracetamol (acetaminophen), an analgesic and antipyretic. The medication is indicated for the symptomatic relief of moderate pain and joint swelling associated with various inflammatory conditions, including osteoarthritis, rheumatoid arthritis, and acute gouty arthritis. By selectively inhibiting the COX-2 enzyme, the etoricoxib component reduces the production of pro-inflammatory prostaglandins while minimizing the gastrointestinal side effects typically associated with non-selective NSAIDs. Paracetamol provides complementary analgesic effects, making the combination effective for managing acute and chronic musculoskeletal pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Atrocoxib-P.